NCT00407121撤回3 期
Intravitreal Bevacizumab for the Treatment of Neovascular Membranes in Patients With Intraocular Inflammation
Asociación para Evitar la Ceguera en México1 个研究点 分布在 1 个国家开始时间: 2006年12月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 撤回
- 发起方
- 试验地点
- 1
- 主要终点
- Best corrected visual acuity
研究概览
简要总结
Intravitreal injection of Bevacizumab in patients with Neovascular Membranes secondary to intraocular inflammation. We injected a single injection of Bevacizumab (2.5 mg/0.1 ml) and evaluate visual acuity , Fluorescein angiogram and retinal thickness by Optical Coherence Tomography (OCT) in 4 patients with Vogt Koyanagi Harada disease, 1 patient with Serpiginous Choroidopathy and 1 patient with Multifocal Choroiditis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 25 Years 至 60 Years(Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Clinical Diagnose
- •Patient Consent
- •Chronic stage of inflammation
排除标准
- •age lower than 30 yo.
- •Systemic condition
结局指标
主要结局
Best corrected visual acuity
Retinal thickness by OCT
Leakage in Fluorescein angiogram
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
进行中(未招募)
不适用
Intravitreal Bevacizumab (Avastin) for neovascular age-related macular degeneration - NDViasual acuity lossMedDRA version: 9.1Level: SOCClassification code 10015919Term: Eye disordersEUCTR2006-004320-36-ITAZIENDA OSPEDALIERA SENESE
尚未招募
不适用
Intravitreal Bevaxizumab injection for intraocular neovasculalization in childreretinopathy of prematurityJPRN-UMIN000007465Tokushima university hospital10
已完成
不适用
Intravitreal bevacizumab injection for intraocular neovascularization in childreRetinopathy of prematurityJPRN-UMIN000014316Kansai Medical University15
终止
2 期
Intravitreal Bevacizumab for Age-Related Macular DegenerationAge Related Macular DegenerationNCT00347165Asociación para Evitar la Ceguera en México50
已完成
1 期
Intravitreal Bevacizumab in Agioid StreaksAngioid StreaksChoroidal NeovascularizationNCT00406250University of Campania "Luigi Vanvitelli"5
